Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

DSpace/Manakin Repository

Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

Citable link to this page

 

 
Title: Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?
Author: Kong, Xiangyi; Kong, Yanguo

Note: Order does not necessarily reflect citation order of authors.

Citation: Kong, Xiangyi, and Yanguo Kong. 2017. “Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?” OncoTargets and therapy 10 (1): 1335-1344. doi:10.2147/OTT.S120341. http://dx.doi.org/10.2147/OTT.S120341.
Full Text & Related Files:
Abstract: The aim of this study was to summarize the findings of previous studies focusing on whether the risks of certain neurotoxicities are correlated to the programmed death 1 (PD-1) inhibitor nivolumab versus other chemotherapy or immunotherapy drugs. Six eligible studies, including 3,023 patients, were considered in the meta-analysis. The risk ratios (RRs) of fatigue, headache, dysgeusia, vertigo, paresthesia, anxiety or malaise and peripheral neuropathy were 0.908 (95% confidence interval [95% CI]: 0.724, 1.138; P=0.402), 0.841 (95% CI: 0.606, 1.168; P=0.302), 0.423 (95% CI: 0.132, 1.357; P=0.148), 0.762 (95% CI: 0.475, 1.223; P=0.261), 0.411 (95% CI: 0.232, 0.730; P=0.002), 1.049 (95% CI: 0.094, 11.752; P=0.969) and 0.192 (95% CI: 0.039, 0.935; P=0.041), respectively. Our analysis supported that the PD-1 inhibitor nivolumab did not cause increased or decreased risks of fatigue, headache, dysgeusia, vertigo and anxiety or malaise and was associated with decreased risks of paresthesia and peripheral neuropathy as compared with controls. These outcomes indicated that although clinicians should be attentive of the side effects of nivolumab, in terms of nervous system side effects, nivolumab is generally safe.
Published Version: doi:10.2147/OTT.S120341
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338929/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072099
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters